Hairy cell leukemia
Leukemic reticuloendotheliosis; HCL; Leukemia - hairy cell
Hairy cell leukemia (HCL) is an unusual cancer of the blood. It affects B cells, a type of white blood cell (lymphocyte).
HCL is caused by the abnormal growth of B cells. The cells look "hairy" under the microscope because they have fine projections extending from their surface.
HCL usually leads to a low number of normal blood cells.
The cause of this disease is unknown. Certain genetic changes (mutations) in the cancer cells may be the cause. It affects men more often than women. The average age of diagnosis is 55.
Symptoms of HCL may include any of the following:
- Easy bruising or bleeding
- Heavy sweating (especially at night)
- Fatigue and weakness
- Feeling full after eating only a small amount
- Recurrent infections and fevers
- Pain or fullness in the upper left belly (enlarged spleen)
- Swollen lymph glands
- Weight loss
Exams and Tests
Blood tests that may be done include:
Treatment may not be needed for the early stages of this disease. Some people may need an occasional blood transfusion.
If treatment is needed because of very low blood counts, chemotherapy drugs can be used.
In most cases, chemotherapy can relieve the symptoms for many years. When the signs and symptoms go away, you are said to be in remission.
Removing the spleen may improve blood counts, but is unlikely to cure the disease. Antibiotics can be used to treat infections. People with low blood counts may receive growth factors and, possibly, transfusions.
Most people with HCL can expect to live 10 years or longer after diagnosis and treatment.
The low blood counts caused by hairy cell leukemia can lead to:
- Excessive bleeding
When to Contact a Medical Professional
There is no known way to prevent this disease.
National Cancer Institute website. Hairy cell leukemia treatment (PDQ) health professional version.
Ravandi F. Hairy cell leukemia. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018:chap 78.
Last reviewed on: 5/27/2020
Reviewed by: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.